mazon medical logo
Provider Login

How do you know if your patient’s incontinence is from Sacral Nerve Dysfunction?

Using the UroVal® Bulbocavernosus Reflex System (BRS)

UroVal® is an FDA-cleared, noninvasive system that objectively measures the bulbocavernosus reflex, a key sacral nerve (S2–S4) reflex involved in bladder, bowel, and sexual function.
Order More Tips!

What is UroVal?

UroVal BRS: Screening for sacral nerve dysfunction.

The UroVal Bulbocavernosus Reflex System (BRS) screens for sacral nerve (S2-S4) dysfunction which may cause urinary incontinence, fecal incontinence, and sexual dysfunction. Many healthcare providers do not test for the Bulbocavernosus Reflex (BCR) because the traditional manual exam is invasive, uncomfortable, and does not go beyond merely assessing the presence or absence of the reflex. UroVal BRS can objectively quantify the latency time (delay) of the reflex measured in milliseconds, giving the provider usable information to determine if the patient has an abnormal reflex that may be caused by sacral nerve dysfunction. A UroVal BRS screening combines surface electromyography (EMG) with mechanical stimulation without any electrical stimulation or bodily insertion.
learn more

Benefits Of UroVal

Convenient

UroVal is an easy-to-use test for physicians to assess a patient’s sacral nerve function.

Takes Less Time

UroVal assessments can be done in minutes with reports generated instantly.

Lower Risk of Infections

Invasive techniques can spread various infections through the anal region, whereas UroVal’s external placement may reduce this risk.

Instant Report

Clinicians get an instant report with the results of the UroVal’s reflex latency time.

Makes Assessment Easy

UroVal works with a simple mechanical tap and EMG, making it quick and easy to measure the bulbocavernosus reflex.

Free from Electrical Stimulation

No requirement for electrical stimulation to elicit the reflex.

Reimbursement

  • Average CMS allowable nationwide is $255.22
  • Billing support is available from our billing consultant and is available to provide counseling tailored to your practice.
  • Assistance with any denials.

2026 Average Medicare Allowable* 
$255.22

UNDERSTAND: This information was retrieved from http://www.cms.hhs.gov/apps/pfslookup/step1.asp It is provided as a courtesy for illustration purposes only. This does not in any way guarantee actual payment. Your local insurers may pay under their own particular guidelines. Review all information with your medical billing professionals. 

Interested in a Two- Week Trial?

Mazon™ Medical understands that adopting new diagnostic technology requires both clinical confidence and operational clarity. The UroVal® Two-Week Trial Program provides a low-risk, hands-on opportunity for your practice to evaluate the UroVal® BRS System in real patient workflows.

On-Site Clinical Training

A live, in-office session focused on system setup, test administration, and interpretation of quantitative BCR latency results. Practices are encouraged to identify appropriate patients in advance.

Workflow Support

Hands-on guidance to integrate UroVal into your existing clinic workflow, supporting efficient use and minimal disruption to daily operations.

Two Weeks of Routine Clinical Use & Reimbursement

The UroVal® BRS System remains in your office for two weeks, allowing integration into normal clinic flow. Eligible tests may be billed using CPT® 51792. The national average Medicare allowable is $255.*

Contact Us to Schedule Your Trial

Testimonials

“Our practice at UNLV medicine has utilized the BR latency evaluation procedure for more than 4 years and have found it to be an exceptional and fundamental piece of information in determining patient diagnosis and best treatment options.”

Adam V. Levy, MD Associate Professor, Department of Obstetrics and Gynecology, UNLV

“UroVal® is a critical development in the care of urology and  urogyn patients. It marks a shift to more objective evaluation and improved patient treatment.“

Aaron Grotas,MD Board Certified Urologist, Mt. Sinai

“UROVAL offers actionable diagnostic information that can influence clinical decision-making. As a practicing urogynecologist, I see clear potential for this technology to support more informed patient care.“

Cheau Williams, MD, FACOG, FACS, URPS

Contact Us

Our team

We are ready to serve you

Brad Cole

Brad Cole

Managing Director & EVP of Sales, Chairman of Vijuvia Life Centers LLC

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Marcus McGehee

Marcus McGehee

Digital Marketing Coordinator

Dave Walker

Dave Walker

Chief Operations Officer

Amy Dittmar

Amy Dittmar

Director of Customer Service

Citations:

  1. (J.Blaivas, A. Zayed, K.Labib, 1981)
  2. Devine, Evangelidis, Hall”Bulbocavernosus Reflex: Does it have a role in the treatment of detrusor instability?”
  3. Levy, Bradley, Prachi, Cross:”Use of Bulbocavernosus Reflex directed pelvic floor rehabilitation for treatment of urinary incontinence as an objective measure of treatment effectiveness”
  4. Direct Supervision §§ 410.32 (b) (ii)
  5. www.cms.gov/apps/physician-fee-schedule/overview.aspx.
  6. Granata G, Padua L, Rossi F, De Franco P, Coraci D, Rossi V. Electrophysiological study of the bulbocavernosus reflex: normative data. Funct Neurol. 2013;28(4):293-295. doi:10.11138/FNeur/2013.28.4.293

UroVal Products are Proudly Made and Manufactured in the USA